Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon (AGN) has received positive feedback from the United Kingdom Medicines and Healthcare Products Regulatory Agency
  • The feedback was related to the company’s planned Phase 1/2a stroke study with AP-188 (“N,N-dimethyltryptamine” or “DMT”)
  • Algernon CEO Christopher Moreau sat down with Dave Jackson to discuss the feedback and the company’s future plans for DMT
  • The company plans to file a Clinical Trial Authorisation (CTA) application for the study as soon as possible
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) is down 9.09 per cent on the day, trading at C$0.05 per share at 1pm ET

Algernon (AGN) received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency.

The feedback was related to the company’s planned Phase 1/2a stroke study with AP-188 (“N,N-dimethyltryptamine” or “DMT”), a known psychedelic compound that is part of the tryptamine family.

Algernon CEO Christopher Moreau sat down with Dave Jackson to discuss the feedback and the company’s future plans for DMT.

“We were very encouraged by today’s meeting with the UK MHRA. The feedback we received was very helpful and we look forward to working with the agency as we move forward with the important work of investigating DMT as a possible therapy for stroke patients globally.”

As a result of the meeting, the company plans to file a Clinical Trial Authorisation (CTA) application for the study as soon as possible. Based on the feedback received, Algernon is also considering focusing on DMT as a possible treatment for acute stroke for the Phase 2a part of the study, in addition to investigating DMT as an adjunctive treatment for stroke rehabilitation therapy.

The company is planning to conduct the Phase 1 part of the study at Hammersmith Medicines Research in London, UK and is now targeting to begin the study in January 2022.

N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.

Algernon Pharmaceuticals is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds.

Algernon Pharmaceuticals Inc. (AGN) is down 9.09 per cent on the day, trading at C$0.05 per share at 1pm ET.

More From The Market Herald
Theratechnologies - CEO, Paul Lévesque.

" Theratechnologies (TSX:TH) receives 2021 ADRIQ Innovation Award

Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category.

" Elixxer Ltd. (TSXV:ELXR) welcomes new director

Elixxer (ELXR) is pleased to welcome Mr. Jeremy Green to the corporation’s board of directors. 

" Psyence Group (CSE:PSYG) to speak at the annual Global Wellness Summit

Psyence Group (PSYG) will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit.

" Leveljump Healthcare Corp. (TSXV:JUMP) announces investment in Real Time Medical

Leveljump Healthcare (JUMP) has agreed to acquire a 14.6 per cent equity interest in Real Time Medical.